RPAM
STOK icon

Rhenman & Partners Asset Management’s Stoke Therapeutics STOK Stock Holding History

Rhenman & Partners Asset Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.7M Sell
83,000
-133,000
-62% -$4.36M 0.33% 73
2025
Q4 		$6.86M Sell
216,000
-34,000
-14% -$1.02M 0.64% 56
2025
Q3 		$5.88M Buy
+250,000
New +$4.28M 0.65% 48

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Rhenman & Partners Asset Management's STOK Position: Q1 2026 in Review

Rhenman & Partners Asset Management reduced its Stoke Therapeutics (STOK) stake by 62% in Q1 2026, selling an estimated $4.36M and leaving 83,000 shares worth $2.7M. The position accounts for 0.33% of the portfolio, ranked #73.

Rhenman & Partners Asset Management first reported a position in STOK in Q3 2025 and has held it in 3 quarters since. The position peaked at $6.86M in Q4 2025. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • Rhenman & Partners Asset Management held 83,000 shares of Stoke Therapeutics worth $2.7M as of Q1 2026.
  • Rhenman & Partners Asset Management sold 133,000 Stoke Therapeutics shares in Q1 2026, an estimated $4.36M.
  • Stoke Therapeutics made up 0.33% of Rhenman & Partners Asset Management's portfolio in Q1 2026, its #73 holding.
  • Rhenman & Partners Asset Management first reported a position in Stoke Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Rhenman & Partners Asset Management's Stoke Therapeutics position peaked at $6.86M in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2026, filed 14 May 2026.